Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
22.07
-0.29 (-1.30%)
At close: Oct 30, 2026, 4:00 PM EDT
22.40
+0.33 (1.50%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or 4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
$252,026
Profits / Employee
-$105,501
Market Cap
2.74B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Arcus Biosciences | 601 |
| Recursion Pharmaceuticals | 600 |
| Biohaven | 274 |
| Celldex Therapeutics | 198 |
| Precigen | 160 |
| Pharvaris | 148 |
| Aurinia Pharmaceuticals | 128 |
ZLAB News
- 7 days ago - Zai Lab's Zoci Shows 82% Response Rate in Early Lung Cancer Study - MarketBeat
- 7 days ago - Zai Lab Transcript: Investor update - Transcripts
- 7 days ago - Zai Lab Press release: Investor update - Filings
- 7 days ago - Zai Lab Slides: Investor update - Filings
- 8 days ago - Zai Lab Limited Announces $250 Million Private Placement - Nasdaq
- 8 days ago - Zai Lab reports results from Phase 1b trial of zocilurtatug pelitecan - TheFly
- 8 days ago - Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer - Business Wire
- 8 days ago - Zai Lab announces $250M private placement - TheFly